Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on May 19, 2018 in Leukemia | 0 comments

In a nutshell

This study aimed to compare the effectiveness and tolerability of micafungin (Mycamine) and posaconazole (Noxafil) in acute leukemia patients undergoing chemotherapy. This study concluded that micafungin was effective as an antifungal prophylaxis in these patients.

Some background

Invasive fungal infections (IFIs) are common in patients receiving intensive chemotherapy for acute leukemia. IFIs are associated with reduced quality of life and patient outcomes. Antifungal prophylaxis (treatment to prevent disease) is used for patients who have prolonged neutropenia due to chemotherapy. Neutropenia is an abnormally low levels of neutrophils (white blood cells) that help fight infections.

Posaconazole is a commonly used antifungal, but it is associated with multiple negative side effects and must be taken by mouth. Micafungin is another type of antifungal that has been shown to be effective. It can be delivered through an IV (tube inserted directly into a vein). It is not clear which of these antifungals would be more effective and tolerable.

Methods & findings

This study involved 113 patients with acute leukemia or myelodysplastic syndrome undergoing chemotherapy. 58 patients were treated with micafungin and 55 were treated with posaconazole. Patients were followed for 12 weeks to measure rates of antifungal failure. This included early stopping of treatment due to infection, intolerance, adverse event, or death.

Prophylaxis failure occurred in 34.5% of patients in the micafungin group compared to 52.7% in the posaconazole group. Micafungin failures were largely due to antifungal treatment. Posaconazole failures were mostly due to gastrointestinal intolerance or adverse effects. The average number of days on prophylaxis was 16 for the micafungin group compared to 13 for the posaconazole group.

Fungal infection incidence and survival were similar between the groups.

The bottom line

This study concluded that micafungin is suitable for use as antifungal prophylaxis in patients with AL.

What’s next?

Consult your physician about antifungal prophylaxis during chemotherapy treatment.

Published By :

The Journal of infection

Date :

May 07, 2018

Original Title :

Micafungin Versus Posaconazole Prophylaxis in Acute Leukemia or Myelodysplastic Syndrome: A Randomized Study.

click here to get personalized updates